Ravinder Bhagrath, MD
Nephrology · Pikeville, KYNPI 1629181458
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,350 of the $84,130 with a category attached, or 77.7%. 27 manufacturers reported payments, led by Lilly USA, LLC at 41.4% of the total. Reporting peaked in 2019 at $22,091 and has fallen 95.3% since, to $1,037 in 2025. Among nephrology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $168.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$35K
- AstraZeneca$26K
- Boehringer Ingelheim$11K
- Bayer$9K
- Otsuka America Pharmaceutical, Inc.$576
- Medtronic$539
- plus $3K from 21 others
What the payments were for
- Consulting fees$4,9006%
- Speaking & faculty fees$65,35078%
- Travel & lodging$4,7676%
- Food & beverage$8,67210%
- Education$4411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 87 | $34,822 |
| AstraZeneca | 122 | $26,055 |
| Boehringer Ingelheim | 57 | $10,834 |
| Bayer | 18 | $8,515 |
| Otsuka America Pharmaceutical, Inc. | 30 | $576 |
| Medtronic(2 entities) | 34 | $539 |
| Sanofi-aventis U.S. LLC | 30 | $465 |
| Novo Nordisk | 20 | $353 |
| Corcept Therapeutics | 12 | $232 |
| AbbVie | 4 | $202 |
| Calliditas Therapeutics US Inc. | 11 | $200 |
| Xeris Pharmaceuticals, Inc. | 11 | $175 |
| Amgen | 7 | $151 |
| Johnson & Johnson | 4 | $150 |
| Travere Therapeutics, Inc. | 10 | $148 |
| Merck | 11 | $146 |
| Novartis | 9 | $144 |
| Mallinckrodt Hospital Products Inc. | 5 | $143 |
| Vifor Pharma, Inc. | 5 | $79 |
| Abbott | 2 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $28 |
| OPKO Pharmaceuticals, LLC | 2 | $28 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Dexcom, Inc. | 2 | $27 |
| GSK | 1 | $20 |
| Pfizer | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,130 in reported general payments places this provider in the 95th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 457 | $360,500 |
| JardianceEmpagliflozin | 422 | $325,755 |
| OzempicSemaglutide | 203 | $224,050 |
| TrulicityDulaglutide | 154 | $165,994 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 145 | $131,279 |
| VelphoroSucroferric Oxyhydroxide | 24 | $112,880 |
| MounjaroTirzepatide | 58 | $61,010 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $20,509 |
| Sevelamer Carbonate | 83 | $19,138 |
| Lanthanum Carbonate | 15 | $17,181 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $15,748 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $14,127 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $13,036 |
| RybelsusSemaglutide | 11 | $12,208 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $12,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $26,055 | $373,536478 claims |
| Boehringer IngelheimJardiance | $10,834 | $325,755422 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $353 | $240,343230 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $34,822 | $227,004212 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $465 | $131,279145 claims |
| BayerKerendia | $8,515 | $6,99512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 nephrology providers in Kentucky.
Other nephrology in Pikeville
- Danny WooLouisville$427K
- Dawn CasterLouisville$193K
- Javier Neyra LozanoLexington$181K
- Kurt SowersHazard$119K
- Nizar AttallahLouisville$113K
- Shafic Abdul Wahab El HindiLouisville$45K
- George AronoffLouisville$26K
- Sadiq AhmedLexington$17K
- Muhammad FarhanMt Sterling$13K
- Madhumathi RaoLexington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.